Disclosed is a solid pharmaceutical formulation comprising (a) cilostazol, (b) (b) a pre-gelatinized starch in an amount of 10 to 90 percent by weight based on the whole weight of the formulation, (c) one or more kinds of enteric ingredients selected from the group consisting of hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, carboxymethylethylcellulose, methacrylic acid copolymer L and methacrylic acid copolymer S, and (d) an organic acid, as a matrix.
